Dzhamilya S. Dzhabrailova
Dzhamilya S. Dzhabrailova has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Azizzhon D. Zikiryachodzhaev
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiology Center, Ministry of Health of Russia
10 shared publications - Fedor N. Usov
P.A. Herzen Moscow Oncology Research Institute – a branch of the National Medical Radiology Research Center, Ministry of Health of Russia
7 shared publications - Ilona S. Duadze
Hertsen Moscow Oncology Research Center
6 shared publications - Daria Valerievna Bagdasarova
National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Koroleva St. 4, 249036 Obninsk, Russia
5 shared publications - Marianna V. Starkova
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiology Center, Ministry of Health of Russia
5 shared publications - Кирилл Владимирович Максимов
P.A. Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
4 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 72 (4) , 2456
Perspectives of Omission of Axillary Lymph Node Dissection in Node-Positive Breast Cancer Patients After Neoadjuvant Chemotherapy: A Systematic Review
Введение. В данном систематическом обзоре проанализировано влияние биопсии сторожевого лимфатического узла (БСЛУ) на долгосрочные онкологические результаты у пациенток с клинически верифицированным поражением аксиллярных лимфатических узлов при раке молочной железы после неоадъювантной химиотерапии (НАПХТ) и достижение клинического ответа. Основная цель — оценить, обеспечивает ли БСЛУ при достижении клинического ответа в регионарных зонах сопоставимые показатели общей (ОВ) и безрецидивной выживаемости (БРВ) по сравнению со стандартной аксиллярной лимфодиссекцией (АЛД). Материалы и методы. Поиск литературы проведен в марте 2025 г. в базах PUBMED и Google Scholar с использованием ключевых слов breast neoplasm, node-positive, neoadjuvant chemotherapy, long-term survival, а также ручным просмотром списков ссылок включенных статей. В обзор включались рандомизированные контролируемые исследования и ретроспективные когортные исследования, оценившие отдаленные показатели ОВ, БРВ и частоту аксиллярных рецидивов в группе пациентов с клинически верифицированным поражением аксиллярных лимфатических узлов и полным клиническим регрессом после НАПХТ в зависимости от выполненного хирургического вмешательства на регионарном лимфоколлекторе. Отбор литературы и извлечение данных выполнялись двумя независимыми рецензентами по рекомендациям PRISMA с оценкой риска смещений шкалой Newcastle–Ottawa. Результаты. Из 341 найденного источника отобрано 20 исследований для систематического обзора. Пятилетняя ОВ в группах БСЛУ и АЛД составила 93,3 и 80,0 % соответственно, а БРВ — 84,7 и 73,2 % (p = 0,001). Частота аксиллярных рецидивов в обеих группах оставалась низкой и статистически не различалась (0,3–0,9 % для БСЛУ против 0,4–0,6 % для АЛД). Выводы. Объем хирургического вмешательства в регионарных зонах не показал статистически значимого влияния на отдаленные показатели выживаемости пациенток при раке молочной железы с поражением лимфатических узлов и полной клинической регрессией после НАПХТ, однако требуются результаты крупных рандомизированных исследований высокого качества с отдельным анализом подгрупп.
- 15 September 2026
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 72 (4) , 2456
Open AccessPerspectives of Omission of Axillary Lymph Node Dissection in Node-Positive Breast Cancer Patients After Neoadjuvant Chemotherapy: A Systematic Review
Введение. В данном систематическом обзоре проанализировано влияние биопсии сторожевого лимфатического узла (БСЛУ) на долгосрочные онкологические результаты у пациенток с клинически верифицированным поражением аксиллярных лимфатических узлов при раке молочной железы после неоадъювантной химиотерапии (НАПХТ) и достижение клинического ответа. Основная цель — оценить, обеспечивает ли БСЛУ при достижении клинического ответа в регионарных зонах сопоставимые показатели общей (ОВ) и безрецидивной выживаемости (БРВ) по сравнению со стандартной аксиллярной лимфодиссекцией (АЛД). Материалы и методы. Поиск литературы проведен в марте 2025 г. в базах PUBMED и Google Scholar с использованием ключевых слов breast neoplasm, node-positive, neoadjuvant chemotherapy, long-term survival, а также ручным просмотром списков ссылок включенных статей. В обзор включались рандомизированные контролируемые исследования и ретроспективные когортные исследования, оценившие отдаленные показатели ОВ, БРВ и частоту аксиллярных рецидивов в группе пациентов с клинически верифицированным поражением аксиллярных лимфатических узлов и полным клиническим регрессом после НАПХТ в зависимости от выполненного хирургического вмешательства на регионарном лимфоколлекторе. Отбор литературы и извлечение данных выполнялись двумя независимыми рецензентами по рекомендациям PRISMA с оценкой риска смещений шкалой Newcastle–Ottawa. Результаты. Из 341 найденного источника отобрано 20 исследований для систематического обзора. Пятилетняя ОВ в группах БСЛУ и АЛД составила 93,3 и 80,0 % соответственно, а БРВ — 84,7 и 73,2 % (p = 0,001). Частота аксиллярных рецидивов в обеих группах оставалась низкой и статистически не различалась (0,3–0,9 % для БСЛУ против 0,4–0,6 % для АЛД). Выводы. Объем хирургического вмешательства в регионарных зонах не показал статистически значимого влияния на отдаленные показатели выживаемости пациенток при раке молочной железы с поражением лимфатических узлов и полной клинической регрессией после НАПХТ, однако требуются результаты крупных рандомизированных исследований высокого качества с отдельным анализом подгрупп.
- Open Access
- 21 August 2026
- Published by Publishing House ABV Press in MD-Onco
- Vol. 6 (2) , 33-40
Omission of sentinel lymph node biopsy in early-stage breast cancer: ongoing trial at the P.A. Herzen Moscow Oncology Research Institute
Background. Sentinel lymph node biopsy (SLNB) is the standard of regional staging in early-stage breast cancer (BC). However, contemporary randomized trials (SOUND, INSEMA, NAUTILUS) demonstrate the feasibility of safe axillary surgical de-escalation in a defined subset of patients with clinically node-negative (cN0) disease. Given the low rate of axillary lymph node metastases and the limited sensitivity of SLNB, this procedure may represent overtreatment in a proportion of patients. Aim. To evaluate the oncological safety and clinical impact of SLNB omission in patients with early-stage breast cancer and clinically intact axillary lymph nodes, and to define approaches to adjuvant therapy optimization in this cohort. Materials and methods. A prospective randomized non-inferiority trial is being conducted at the P.A. Herzen Moscow Oncology Research Institute. Patients with early-stage BC (cTis–cT2, cN0) were randomized 1:1 to SLNB or SLNB omission. In patients with cT1c–T2 disease, intraoperative fine-needle aspiration biopsy of the sentinel lymph node was additionally performed using a fan-shaped technique. The primary endpoint is disease-free survival. Secondary endpoints include overall survival, distant metastasis-free survival, locoregional and axillary recurrence rates, and quality-of-life characteristics. Results. The preliminary analysis included 151 patients. In the cT1a–b cohort assigned to SLNB omission, no lymph node metastases were identified. In the SLNB control group, metastases were detected in 12.5 % of patients, with involvement limited to no more than one lymph node in all cases. In the cT1c–T2 cohort, the metastatic involvement rate was 16.5 %. Intraoperative fine-needle aspiration biopsy of the sentinel lymph node demonstrated a sensitivity of 57.1 %, specificity of 100 %, positive predictive value of 100 %, and negative predictive value of 92.8 %. Favorable biological subtypes (luminal tumors) and low-to-intermediate histological grades predominated in the study population. Conclusion. Preliminary findings suggest potential oncological safety of SLNB omission in carefully selected patients with early-stage breast cancer and cN0 status. Rigorous preoperative axillary assessment using imaging modalities is a prerequisite. Further patient recruitment and extended follow-up are required to enable definitive evaluation of long-term oncological outcomes and to refine criteria for axillary surgical de-escalation.
- 21 August 2026
- Published by Publishing House ABV Press in MD-Onco
- Vol. 6 (2) , 33-40
Open AccessOmission of sentinel lymph node biopsy in early-stage breast cancer: ongoing trial at the P.A. Herzen Moscow Oncology Research Institute
Background. Sentinel lymph node biopsy (SLNB) is the standard of regional staging in early-stage breast cancer (BC). However, contemporary randomized trials (SOUND, INSEMA, NAUTILUS) demonstrate the feasibility of safe axillary surgical de-escalation in a defined subset of patients with clinically node-negative (cN0) disease. Given the low rate of axillary lymph node metastases and the limited sensitivity of SLNB, this procedure may represent overtreatment in a proportion of patients. Aim. To evaluate the oncological safety and clinical impact of SLNB omission in patients with early-stage breast cancer and clinically intact axillary lymph nodes, and to define approaches to adjuvant therapy optimization in this cohort. Materials and methods. A prospective randomized non-inferiority trial is being conducted at the P.A. Herzen Moscow Oncology Research Institute. Patients with early-stage BC (cTis–cT2, cN0) were randomized 1:1 to SLNB or SLNB omission. In patients with cT1c–T2 disease, intraoperative fine-needle aspiration biopsy of the sentinel lymph node was additionally performed using a fan-shaped technique. The primary endpoint is disease-free survival. Secondary endpoints include overall survival, distant metastasis-free survival, locoregional and axillary recurrence rates, and quality-of-life characteristics. Results. The preliminary analysis included 151 patients. In the cT1a–b cohort assigned to SLNB omission, no lymph node metastases were identified. In the SLNB control group, metastases were detected in 12.5 % of patients, with involvement limited to no more than one lymph node in all cases. In the cT1c–T2 cohort, the metastatic involvement rate was 16.5 %. Intraoperative fine-needle aspiration biopsy of the sentinel lymph node demonstrated a sensitivity of 57.1 %, specificity of 100 %, positive predictive value of 100 %, and negative predictive value of 92.8 %. Favorable biological subtypes (luminal tumors) and low-to-intermediate histological grades predominated in the study population. Conclusion. Preliminary findings suggest potential oncological safety of SLNB omission in carefully selected patients with early-stage breast cancer and cN0 status. Rigorous preoperative axillary assessment using imaging modalities is a prerequisite. Further patient recruitment and extended follow-up are required to enable definitive evaluation of long-term oncological outcomes and to refine criteria for axillary surgical de-escalation.
- 17 December 2025
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 6 (4) , 46-58
Fertility preservation in women with BRCA1/2‑related cancers: contemporary strategies, international recommendations, and a multidisciplinary approach
Inherited mutations in the BRCA1/BRCA2 genes significantly increase the risk of breast and ovarian cancer in women of reproductive age, posing a clinical and socioeconomic challenge due to loss of fertility during cancer treatment and preventive interventions. The expansion of genetic testing programs is shifting the focus to proactive management of reproductive potential, requiring the integration of oncology, reproductive medicine, and medical genetics. The novelty of this review lies in its comprehensive synthesis of data on the impact of treatment and prevention of BRCA-associated cancer on fertility and a critical assessment of the effectiveness of fertility preservation strategies. Purpose of the study . To summarize and analyze current advances, clinical guidelines, and unresolved issues related to preserving reproductive function in women carrying BRCA1/BRCA2 mutations. Materials and methods . A systematic search of PubMed/MEDLINE, Embase, the Cochrane Library, and Web of Science was performed, along with an analysis of international guidelines (ESHRE (European Society of Human Reproduction and Embryology), ASCO (American Society of Clinical Oncology), ASRM (American Society for Reproductive Medicine), NCCN (National Comprehensive Cancer Network), ESMO (European Society for Medical Oncology)). Keywords: “BRCA1,” “BRCA2,” “fertility preservation,” “oocyte cryopreservation,” “embryo cryopreservation,” “ovarian tissue cryopreservation,” “PGT-M,” “PARP inhibitors,” and “chemotherapy gonadotoxicity.”, in the period of 2005–2025. Studies with incomplete data, duplicates, reviews of low methodological quality, and case series with fewer than 10 observations were excluded. Priority was given to meta-analyses, RCTs, large cohorts, and consensus reports. Results. The included studies included cancer patients before and after treatment, BRCA carriers with and without prophylactic strategies, and IVF/ICSI cohorts with cryopreservation. Alkylating agents and taxanes have been shown to increase the risk of premature ovarian failure, while GnRH agonists partially reduce the risk of ovarian toxicity. The efficacy of oocyte and embryo cryopreservation in BRCA-positive women is comparable to the population-based efficacy with optimized stimulation (GnRH antagonists, letrozole-containing protocols). Ovarian tissue cryopreservation is applicable in urgently needed patients but requires oncoprotective assessment. PGT-M ensures the selection of mutation-free embryos. Multidisciplinary pathways improve the timelines of referrals and the completion rate of fertility preservation programs Conclusion. Early identification of BRCA-positive women and the integration of a gynecologic oncologist, reproductive specialist, and geneticist enable personalized strategy selection: gamete/embryo cryopreservation, ovarian tissue, pharmacoprotection, and PGT-M. Standardized stimulation protocols and therapy timing, long-term safety and fertility data, and economic access models are needed. Improvements in biotechnology and patient pathways improve reproductive outcomes and quality of life.
- 17 December 2025
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 6 (4) , 46-58
Fertility preservation in women with BRCA1/2‑related cancers: contemporary strategies, international recommendations, and a multidisciplinary approach
Inherited mutations in the BRCA1/BRCA2 genes significantly increase the risk of breast and ovarian cancer in women of reproductive age, posing a clinical and socioeconomic challenge due to loss of fertility during cancer treatment and preventive interventions. The expansion of genetic testing programs is shifting the focus to proactive management of reproductive potential, requiring the integration of oncology, reproductive medicine, and medical genetics. The novelty of this review lies in its comprehensive synthesis of data on the impact of treatment and prevention of BRCA-associated cancer on fertility and a critical assessment of the effectiveness of fertility preservation strategies. Purpose of the study . To summarize and analyze current advances, clinical guidelines, and unresolved issues related to preserving reproductive function in women carrying BRCA1/BRCA2 mutations. Materials and methods . A systematic search of PubMed/MEDLINE, Embase, the Cochrane Library, and Web of Science was performed, along with an analysis of international guidelines (ESHRE (European Society of Human Reproduction and Embryology), ASCO (American Society of Clinical Oncology), ASRM (American Society for Reproductive Medicine), NCCN (National Comprehensive Cancer Network), ESMO (European Society for Medical Oncology)). Keywords: “BRCA1,” “BRCA2,” “fertility preservation,” “oocyte cryopreservation,” “embryo cryopreservation,” “ovarian tissue cryopreservation,” “PGT-M,” “PARP inhibitors,” and “chemotherapy gonadotoxicity.”, in the period of 2005–2025. Studies with incomplete data, duplicates, reviews of low methodological quality, and case series with fewer than 10 observations were excluded. Priority was given to meta-analyses, RCTs, large cohorts, and consensus reports. Results. The included studies included cancer patients before and after treatment, BRCA carriers with and without prophylactic strategies, and IVF/ICSI cohorts with cryopreservation. Alkylating agents and taxanes have been shown to increase the risk of premature ovarian failure, while GnRH agonists partially reduce the risk of ovarian toxicity. The efficacy of oocyte and embryo cryopreservation in BRCA-positive women is comparable to the population-based efficacy with optimized stimulation (GnRH antagonists, letrozole-containing protocols). Ovarian tissue cryopreservation is applicable in urgently needed patients but requires oncoprotective assessment. PGT-M ensures the selection of mutation-free embryos. Multidisciplinary pathways improve the timelines of referrals and the completion rate of fertility preservation programs Conclusion. Early identification of BRCA-positive women and the integration of a gynecologic oncologist, reproductive specialist, and geneticist enable personalized strategy selection: gamete/embryo cryopreservation, ovarian tissue, pharmacoprotection, and PGT-M. Standardized stimulation protocols and therapy timing, long-term safety and fertility data, and economic access models are needed. Improvements in biotechnology and patient pathways improve reproductive outcomes and quality of life.
- Open Access
- 3 August 2025
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 21 (2) , 69-74
The role of intraoperative and early postoperative assessment of skin flap perfusion in skin-sparing/subcutaneous mastectomies
The surgical stage is the main one in the complex and combined treatment of patients with breast cancer. After performing skin-sparing and subcutaneous mastectomies, there is a risk of postoperative complications in the form of skin flap necrosis associated with its insufficient perfusion. In order to reduce the incidence of postoperative complications, it is necessary to improve the quality of intraoperative assessment of skin flap perfusion after reconstructive plastic surgery on the mammary gland. This article reviews the literature on current issues of assessing the efficacy and safety of this technique. Indocyanine green angiography has been proposed to assess skin flap perfusion. The method involves intraoperative injection of dye followed by illumination of the skin flap to assess perfusion and remove non-viable tissue.
- 3 August 2025
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 21 (2) , 69-74
Open AccessThe role of intraoperative and early postoperative assessment of skin flap perfusion in skin-sparing/subcutaneous mastectomies
The surgical stage is the main one in the complex and combined treatment of patients with breast cancer. After performing skin-sparing and subcutaneous mastectomies, there is a risk of postoperative complications in the form of skin flap necrosis associated with its insufficient perfusion. In order to reduce the incidence of postoperative complications, it is necessary to improve the quality of intraoperative assessment of skin flap perfusion after reconstructive plastic surgery on the mammary gland. This article reviews the literature on current issues of assessing the efficacy and safety of this technique. Indocyanine green angiography has been proposed to assess skin flap perfusion. The method involves intraoperative injection of dye followed by illumination of the skin flap to assess perfusion and remove non-viable tissue.
- Open Access
- 20 December 2023
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 19 (4) , 43-53
Autologous dura mater grafts in reconstructive surgeries for breast cancer: surgical and aesthetic outcomes
Background. Simultaneous breast reconstruction after subcutaneous or skin-sparing mastectomy using silicone implants is associated with a high risk of postoperative complications. Therefore, the issue of additional shell cover for breast implants is highly relevant. Synthetic and biological implants are believed to be the most effective.Aim. To assess the efficacy and safety of autologous dura mater grafts in reconstructive surgeries for breast cancer patients.Materials and methods. This study included 164 patients who had undergone subcutaneous or skin-sparing mastectomy with simultaneous breast reconstruction using implants and additional shell cover with either autologous dura mater grafts (experimental group, n = 83) or synthetic mesh implants (control group, n = 81) between 2017 and 2022. The mean patients’ age was 41.4 ± 7.2 years (41.2 ± 7.1 years in the experimental group and 41.6 ± 7.2 years in the control group). The mean follow-up time was 38.0 ± 21.4 months (min: 12 months; max: 80 months).Results. The 3-year relapse-free survival rate was 100 %. The 3-year progression-free survival was 97.4 % (95 % confidence interval 92.6–100.0 %). We observed no significant differences in the time to disease progression between the experimental and control group (p = 0.573). The assessment of aesthetic outcomes using a special surgical questionnaire showed excellent cosmetic and psycho-emotional results. Patients in both groups demonstrated comparable cosmetic results (p 0.05); however, psychoemotional satisfaction with surgery results was higher in the experimental group (p0.05). Postoperative complications (primarily capsule contracture) were registered in 18 patients from the experimental group (21.7 %) and 31 patients from the control group (38.3 %) (p0.05). We also calculated the incidence rate ratio (IRR) and found that the difference was due to different follow-up time. Clinically significant capsule contracture was observed in 9 patients from the experimental group (10.8 %). The incidence of capsule contracture was higher among patients who had radiation therapy than in those who had no radiation therapy (15.8 % and 0.0 %, respectively; p0.05).Conclusion. Subcutaneous or skin-sparing mastectomy with simultaneous breast reconstruction using silicone implants and autologous dura mater grafts is a safe and effective surgical method for breast cancer patients. The analysis of the international Breast-Q questionnaire results and surgical questionnaire results demonstrated that all patients had a high quality of life after simultaneous breast reconstruction using an autologous dura mater graft.
- 20 December 2023
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 19 (4) , 43-53
Open AccessAutologous dura mater grafts in reconstructive surgeries for breast cancer: surgical and aesthetic outcomes
Background. Simultaneous breast reconstruction after subcutaneous or skin-sparing mastectomy using silicone implants is associated with a high risk of postoperative complications. Therefore, the issue of additional shell cover for breast implants is highly relevant. Synthetic and biological implants are believed to be the most effective.Aim. To assess the efficacy and safety of autologous dura mater grafts in reconstructive surgeries for breast cancer patients.Materials and methods. This study included 164 patients who had undergone subcutaneous or skin-sparing mastectomy with simultaneous breast reconstruction using implants and additional shell cover with either autologous dura mater grafts (experimental group, n = 83) or synthetic mesh implants (control group, n = 81) between 2017 and 2022. The mean patients’ age was 41.4 ± 7.2 years (41.2 ± 7.1 years in the experimental group and 41.6 ± 7.2 years in the control group). The mean follow-up time was 38.0 ± 21.4 months (min: 12 months; max: 80 months).Results. The 3-year relapse-free survival rate was 100 %. The 3-year progression-free survival was 97.4 % (95 % confidence interval 92.6–100.0 %). We observed no significant differences in the time to disease progression between the experimental and control group (p = 0.573). The assessment of aesthetic outcomes using a special surgical questionnaire showed excellent cosmetic and psycho-emotional results. Patients in both groups demonstrated comparable cosmetic results (p 0.05); however, psychoemotional satisfaction with surgery results was higher in the experimental group (p0.05). Postoperative complications (primarily capsule contracture) were registered in 18 patients from the experimental group (21.7 %) and 31 patients from the control group (38.3 %) (p0.05). We also calculated the incidence rate ratio (IRR) and found that the difference was due to different follow-up time. Clinically significant capsule contracture was observed in 9 patients from the experimental group (10.8 %). The incidence of capsule contracture was higher among patients who had radiation therapy than in those who had no radiation therapy (15.8 % and 0.0 %, respectively; p0.05).Conclusion. Subcutaneous or skin-sparing mastectomy with simultaneous breast reconstruction using silicone implants and autologous dura mater grafts is a safe and effective surgical method for breast cancer patients. The analysis of the international Breast-Q questionnaire results and surgical questionnaire results demonstrated that all patients had a high quality of life after simultaneous breast reconstruction using an autologous dura mater graft.
- Open Access
- 17 May 2023
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 25 (1) , 68-72
Influence of radiation therapy on the development of complications in single-stage autologous breast reconstruction with a DIEP-flap in breast cancer patients: a retrospective study
Breast reconstruction after complex oncological treatment is an urgent issue due to the high incidence of breast cancer. Aim. To analyze the effect of postoperative radiotherapy on the incidence of fat necrosis in single-stage autologous breast reconstruction with a DIEP flap and to evaluate the number of complications in groups with and without postoperative radiotherapy, as well as to determine the risk factors for complications. Materials and methods. The medical records of 34 breast cancer patients who underwent one-stage breast reconstruction using a DIEP flap after skin-sparing/subcutaneous mastectomy with and without subsequent radiation therapy were retrospectively studied. The frequency of complications in groups with and without postoperative radiation therapy was assessed. Results. Complications developed in 22 (64.7%) patients out of 34. Mild complications developed in 6 (17.6%) patients (divergence of the edges of the postoperative wound of the anterior abdominal wall). Complications of moderate severity developed in 12 (35.3%) patients. Severe complications developed in 4 (11.8%) patients. Out of 22 patients, 6 (17.4%) patients developed areas of fat necrosis after remote radiation therapy in the delayed period, 4 (11.8%) patients, without ESWL, also developed fat necrosis of a part of the flap (areas up to 5 cm). Excision of the area of fat necrosis of the flap was performed in 2 (5.9%) cases under local anesthesia, the rest of the areas of fat necrosis were not excised. The percentage of complications was higher in the group of patients with obesity (20.6%), which indicates that obesity is a risk factor for the development of intraoperative and postoperative complications in patients with simultaneous breast reconstruction with a DIEP flap. Conclusion. During radiotherapy after breast reconstruction with a DIEP flap, the incidence of fat necrosis of the flap was higher. Obesity is a risk of intraoperative and postoperative complications in patients with simultaneous increased breast reconstruction with a DIEP flap, since the incidence of complications was in the group of patients with obesity.
- 17 May 2023
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 25 (1) , 68-72
Open AccessInfluence of radiation therapy on the development of complications in single-stage autologous breast reconstruction with a DIEP-flap in breast cancer patients: a retrospective study
Breast reconstruction after complex oncological treatment is an urgent issue due to the high incidence of breast cancer. Aim. To analyze the effect of postoperative radiotherapy on the incidence of fat necrosis in single-stage autologous breast reconstruction with a DIEP flap and to evaluate the number of complications in groups with and without postoperative radiotherapy, as well as to determine the risk factors for complications. Materials and methods. The medical records of 34 breast cancer patients who underwent one-stage breast reconstruction using a DIEP flap after skin-sparing/subcutaneous mastectomy with and without subsequent radiation therapy were retrospectively studied. The frequency of complications in groups with and without postoperative radiation therapy was assessed. Results. Complications developed in 22 (64.7%) patients out of 34. Mild complications developed in 6 (17.6%) patients (divergence of the edges of the postoperative wound of the anterior abdominal wall). Complications of moderate severity developed in 12 (35.3%) patients. Severe complications developed in 4 (11.8%) patients. Out of 22 patients, 6 (17.4%) patients developed areas of fat necrosis after remote radiation therapy in the delayed period, 4 (11.8%) patients, without ESWL, also developed fat necrosis of a part of the flap (areas up to 5 cm). Excision of the area of fat necrosis of the flap was performed in 2 (5.9%) cases under local anesthesia, the rest of the areas of fat necrosis were not excised. The percentage of complications was higher in the group of patients with obesity (20.6%), which indicates that obesity is a risk factor for the development of intraoperative and postoperative complications in patients with simultaneous breast reconstruction with a DIEP flap. Conclusion. During radiotherapy after breast reconstruction with a DIEP flap, the incidence of fat necrosis of the flap was higher. Obesity is a risk of intraoperative and postoperative complications in patients with simultaneous increased breast reconstruction with a DIEP flap, since the incidence of complications was in the group of patients with obesity.
- 1 January 2022
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 11 (4)
Prognostic factors in patients with primary operable breast cancer (cT1-2N0-1M0) after reconstructive plastic surgery with single-stage reconstruction using endoprosthesis
ЦЕЛЬ ИССЛЕДОВАНИЯ Определить факторы неблагоприятного прогноза и бессобытийную выживаемость у больных первично-операбельным раком молочной железы (РМЖ) после одномоментной реконструкции. МАТЕРИАЛ И МЕТОДЫ В работе проанализированы данные 203 больных РМЖ, которым была выполнена кожесохранная/подкожная мастэктомия (КМЭ/ПМЭ) с одномоментной реконструкцией силиконовым эндопротезом в рамках комбинированного или комплексного лечения в период с января 2008 г. по март 2018 г. Средний возраст больных на момент операции составил 45,08±0,65 года (диапазон 18—75 лет). Медиана наблюдения 51 мес (95% ДИ от 49 до 53 мес), средняя длительность наблюдения 60,3±1,9 мес. ПМЭ с одномоментной реконструкцией силиконовым эндопротезом была выполнена у 71,4% больных. РЕЗУЛЬТАТЫ Кумулятивная безрецидивная выживаемость в течение 3 и 5 лет составила 100%, 10 лет — 92,6% (95% ДИ: 81,9—100%). Среднее время до прогрессирования 30,9 мес. Выживаемость без отдаленного метастазирования в течение 3 лет была 97% (95% ДИ: 94,7—99,4%), 10 лет — 91,6% (95% ДИ: 86,7—96,6%). В общей группе больных 10-летняя опухолеспецифическая выживаемость составила 99,3% Наличие лимфоваскулярной инвазии (p=0,048) и метастатического поражения регионарных лимфатических узлов (p=0,008) связано с ухудшением бессобытийной выживаемости. ЗАКЛЮЧЕНИЕ Выполнение КМЭ/ПМЭ с одномоментной реконструкцией силиконовым эндопротезом является безопасным хирургическим методом у больных РМЖ. Риск развития локальных рецидивов и прогрессирования остается высоким в течение 5 ближайших лет после лечения и стабильным в течение следующих 10 лет.
- 1 January 2022
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 11 (4)
Prognostic factors in patients with primary operable breast cancer (cT1-2N0-1M0) after reconstructive plastic surgery with single-stage reconstruction using endoprosthesis
ЦЕЛЬ ИССЛЕДОВАНИЯ Определить факторы неблагоприятного прогноза и бессобытийную выживаемость у больных первично-операбельным раком молочной железы (РМЖ) после одномоментной реконструкции. МАТЕРИАЛ И МЕТОДЫ В работе проанализированы данные 203 больных РМЖ, которым была выполнена кожесохранная/подкожная мастэктомия (КМЭ/ПМЭ) с одномоментной реконструкцией силиконовым эндопротезом в рамках комбинированного или комплексного лечения в период с января 2008 г. по март 2018 г. Средний возраст больных на момент операции составил 45,08±0,65 года (диапазон 18—75 лет). Медиана наблюдения 51 мес (95% ДИ от 49 до 53 мес), средняя длительность наблюдения 60,3±1,9 мес. ПМЭ с одномоментной реконструкцией силиконовым эндопротезом была выполнена у 71,4% больных. РЕЗУЛЬТАТЫ Кумулятивная безрецидивная выживаемость в течение 3 и 5 лет составила 100%, 10 лет — 92,6% (95% ДИ: 81,9—100%). Среднее время до прогрессирования 30,9 мес. Выживаемость без отдаленного метастазирования в течение 3 лет была 97% (95% ДИ: 94,7—99,4%), 10 лет — 91,6% (95% ДИ: 86,7—96,6%). В общей группе больных 10-летняя опухолеспецифическая выживаемость составила 99,3% Наличие лимфоваскулярной инвазии (p=0,048) и метастатического поражения регионарных лимфатических узлов (p=0,008) связано с ухудшением бессобытийной выживаемости. ЗАКЛЮЧЕНИЕ Выполнение КМЭ/ПМЭ с одномоментной реконструкцией силиконовым эндопротезом является безопасным хирургическим методом у больных РМЖ. Риск развития локальных рецидивов и прогрессирования остается высоким в течение 5 ближайших лет после лечения и стабильным в течение следующих 10 лет.
- Open Access
- 29 October 2021
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 17 (3) , 44-50
Autologous dura mater grafts in reconstructive surgeries for breast cancer patients
Reconstructive surgeries have long been considered as an essential part of rehabilitation of breast cancer patients. The majority of patients tend to choose one-stage reconstruction, because this type of surgery ensures rapid emotional and physical recovery. Due to the lack of subcutaneous fat in a substantial proportion of cases, which leads to postoperative complications, the most common surgical tactics now is simultaneous reconstruction after subcutaneous mastectomy with subpectoral implant location and strengthening of the lower breast slope using different materials. So far, there has been no gold standard material for secure covering of the lower pole of the implant. Autologous acellular dura mater grafts are a promising material for breast reconstruction. Studies evaluating biointegration, compatibility, inertness, reactivity, and cost effectiveness of autologous acellular dura mater grafts have determined feasibility of using these grafts in reconstructive surgeries.
- 29 October 2021
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 17 (3) , 44-50
Open AccessAutologous dura mater grafts in reconstructive surgeries for breast cancer patients
Reconstructive surgeries have long been considered as an essential part of rehabilitation of breast cancer patients. The majority of patients tend to choose one-stage reconstruction, because this type of surgery ensures rapid emotional and physical recovery. Due to the lack of subcutaneous fat in a substantial proportion of cases, which leads to postoperative complications, the most common surgical tactics now is simultaneous reconstruction after subcutaneous mastectomy with subpectoral implant location and strengthening of the lower breast slope using different materials. So far, there has been no gold standard material for secure covering of the lower pole of the implant. Autologous acellular dura mater grafts are a promising material for breast reconstruction. Studies evaluating biointegration, compatibility, inertness, reactivity, and cost effectiveness of autologous acellular dura mater grafts have determined feasibility of using these grafts in reconstructive surgeries.
- Open Access
- 26 September 2021
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 8 (3) , 108-117
Breast reconstruction with deep inferior epigastric artery perforator flap (DIEP-flap). History of development
The article is devoted to the actual topic of breast reconstruction with autologous tissues. The article discusses the key stages in the development of breast reconstructive surgery using free flaps using microsurgical techniques. A flap of the anterior abdominal wall, among other techniques, is the method of choice for breast reconstruction today, also because it allows you to achieve the most "natural" result. The authors compares different variants of autologous flaps, describes the advantages of the DIEP flap in comparison with the TRAM flap. Also, special attention is paid to the choice of breast reconstruction method depending on age, constitutional characteristics and the presence of risk factors such as smoking, diabetes mellitus and excess BMI. Analyzing the advantages of breast reconstruction with autograft flaps, the author concludes that there is a higher quality of life and improved outcomes in these patients than in patients who underwent implant-based reconstruction. Based on the literature review, it was found that breast reconstruction with the help of perforating flaps is still an area of innovation and constant progress: research in this area to date is mainly aimed at reducing the morbidity of the donor area and methods for isolating recipient vessels, shortening the rehabilitation period and developing reproducible reconstruction method.
- 26 September 2021
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 8 (3) , 108-117
Open AccessBreast reconstruction with deep inferior epigastric artery perforator flap (DIEP-flap). History of development
The article is devoted to the actual topic of breast reconstruction with autologous tissues. The article discusses the key stages in the development of breast reconstructive surgery using free flaps using microsurgical techniques. A flap of the anterior abdominal wall, among other techniques, is the method of choice for breast reconstruction today, also because it allows you to achieve the most "natural" result. The authors compares different variants of autologous flaps, describes the advantages of the DIEP flap in comparison with the TRAM flap. Also, special attention is paid to the choice of breast reconstruction method depending on age, constitutional characteristics and the presence of risk factors such as smoking, diabetes mellitus and excess BMI. Analyzing the advantages of breast reconstruction with autograft flaps, the author concludes that there is a higher quality of life and improved outcomes in these patients than in patients who underwent implant-based reconstruction. Based on the literature review, it was found that breast reconstruction with the help of perforating flaps is still an area of innovation and constant progress: research in this area to date is mainly aimed at reducing the morbidity of the donor area and methods for isolating recipient vessels, shortening the rehabilitation period and developing reproducible reconstruction method.
- 1 January 2021
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 10 (6) , 100
Diagnosis of the sentinel lymph node during neoadjuvant chemotherapy
В настоящее время значительно расширились показания к проведению химиотерапии на первом этапе лечения. Неоадъювантная химиотерапия показала свою эффективность не только при местно-распространенных, но и при первично-операбельных формах рака молочной железы. В связи с данной тенденцией встал вопрос об оптимальном времени проведения биопсии сторожевого лимфатического узла (БСЛУ). В данной статье рассмотрены достоинства и недостатки выполнения БСЛУ до или после неоадъювантной химиотерапии.
- 1 January 2021
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 10 (6) , 100
Diagnosis of the sentinel lymph node during neoadjuvant chemotherapy
В настоящее время значительно расширились показания к проведению химиотерапии на первом этапе лечения. Неоадъювантная химиотерапия показала свою эффективность не только при местно-распространенных, но и при первично-операбельных формах рака молочной железы. В связи с данной тенденцией встал вопрос об оптимальном времени проведения биопсии сторожевого лимфатического узла (БСЛУ). В данной статье рассмотрены достоинства и недостатки выполнения БСЛУ до или после неоадъювантной химиотерапии.